Research Article Details
| Article ID: | A49154 |
| PMID: | 16137475 |
| Source: | Gastroenterol Hepatol |
| Title: | [Etiopathogenesis of non-alcoholic steatohepatitis]. |
| Abstract: | The <<double impact>> theory is the most widely accepted explanation for the pathogenesis of non-alcoholic steatohepatitis, while insulin resistance is a key factor. In the <<first impact>> the increased afflux of fatty acids to hepatocytes combined with decreased triglyceride elimination and lower fatty acid oxygenation leads to steatosis. The steatosis is not always quiescent, since the accumulated fatty acids are susceptible to a <<second impact>> in which the following factors intervene: a) oxidative stress with an increase in the production of oxygen free radicals which activate transcription factors such as NF-kappa, facilitating the formation of cytokines (tumor necrosis factor-alpha, tumor growth factor beta 1, interleukin-8 and Fas ligands; b) lipid peroxidation with the formation of malondialdehyde and 4-hydroxynonenal, promoting the afflux of inflammatory cells to the liver, depleting antioxidants such as glutathione, inducing the formation of Mallory bodies and increasing collagen synthesis on activating stellate cells, and c) leptin, endotoxins and iron overload, which together induce the lesions of steatohepatitis. |
| DOI: | 10.1157/13077761 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S04 | Anti-oxidative stress | oxidative stress | α-tocopherol: antioxidant | Vitamin E | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D158 | Glutathione | Chemical drug | DB00143 | MGST3; HPGDS; GSTM2; GSTM5; GPX7 cofactor; MGST2; GSS; GSTM1; GSTK1; GSTM3; GSTM4; GPX1 cofactor; GPX2 cofactor; GPX3 cofactor | -- | Under clinical trials | Details |